Archives: Speakers

I believe sustainable success is about developing emotionally intelligent resilient leaders who combine a growth mindset with an unwavering commitment to human-centered technology.

Here is what I am doing with my time now:
✍️ Finishing my book, “AI Uncomplicated,”
🎤 Speaking: Responsible AI and Future of Work
👩🏻‍🏫 Teaching, guest lecturing,
🏛️ Developing Higher Ed. courses & curriculum

Experience:
25+ years in healthcare, business, and consulting + PhD in health informatics from UNT.

Distinguished scientist and global life sciences business leader with strong record of bringing multiple drugs to market and patients

• Led successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca

• Achieved FDA and EMA approval of Zurampic, the first novel MOA for the treatment of gout
in over 50 years

• Led successful commercial licensing of Zurampic and Duzallo to Ironwood Pharmaceuticals and
Grunenthal

• Transformed the AstraZeneca/BMS Diabetes global development and commercial collaboration, and
established Onglyza, Kombiglyze XR and Komboglyze as key growth drivers in the AZ portfolio

• Designed and implemented multiple innovative delivery and partnership models including an
industry leading approach to delivery of outsourced clinical work through development of strategic
partnerships with CROs

• Designed and implemented multiple strategic re-organizations, led major global change
management, whilst delivering improved efficiencies and productivity

Associate Director, Development Business Operations with over 15 years of experience in drafting, reviewing, and negotiating contractual and legal documents within the CRO/Pharmaceutical/Clinical Site environment, for both CROs and for sponsors. I am highly competent and knowledgeable at managing internal and external budgets, including site budgets, cash flow analysis, and revenue recognition through developing a range of cash positive payment schedules. My knowledge in proposal, contract, and budget development has been invaluable in the critical assessment of the multiple aspects of vendor proposals and contracts and in the selection of US and Ex-US vendors including in the evaluation of bid defences.

My experience in tracking and analysing internal and external metrics have helped ensure contractual timelines are met and critical study related milestones are achieved. My proven leadership qualities comprise global line management and project management which are evident through development, advancement and implementation of global contracting processes, template management, and document review processes designed to create efficiencies and ensure client and sponsor satisfaction.

My clinical research experience is supported through my degree in pharmacology which provides essential theoretical knowledge in a number of scientific research fields actively involved in clinical research trials.

A dynamic business leader with over 20 years of commercial experience at both biopharma and vendor companies. Strong scientific background with pharma/biotech clinical development and CRO/CDMO full-service phase I-IV sales experience and a deep understanding of drug development. Prolific networker with global contacts and a track record of negotiating and closing deals.

Bhakti Patel is a strategic clinical operations leader specializing in ophthalmology, medical devices, and drug/device combination trials. As Senior Director of Project Delivery within the Ophthalmology business unit, Bhakti leads global clinical delivery efforts with a focus on cross-functional collaboration, regulatory compliance, and operational efficiency.

With nearly two decades of experience across CRO, pharma, and site networks, she brings deep expertise in clinical trial management across all phases, including vendor oversight, risk mitigation, audit readiness, and data-driven process improvement. Her leadership has supported successful trials in a broad range of therapeutic areas, with particular depth in ophthalmology indications such as geographic atrophy, glaucoma, diabetic macular edema (DME), and gene therapy.

Prior to joining TFS, Bhakti held senior leadership roles at Velocity Clinical Research, Glaukos Corporation, and ORA, where she implemented scalable systems, enhanced site performance, and led inspection readiness across global studies. She is also known for building and mentoring high-performing teams that consistently deliver on time and with quality.

Bhakti holds a bachelor’s degree in Microbiology, Immunology, and Biochemistry and is a certified Lead Auditor. She is deeply committed to patient-centered research, continuous improvement, and empowering teams to drive lasting impact.

Ms. Claire Chin is a strategic leader at the intersection of life sciences investment and AI with over 15 years of cross-sector expertise spanning clinical medicine, strategic consulting, venture capital, and artificial intelligence. As Chief Industrial Advisor and Chief Strategy Officer at INTELLIGEN AI, she spearheads biomedical LLM ecosystem development. Holding an MBA from Kellogg School of Management and a clinical medicine dual degree from Shanghai Jiao Tong University, she uniquely bridges deep healthcare and business domains. As former Managing Director at Alibaba Health, head of investment in biopharma, her track record includes leading a $70M+ life science portfolio and securing Asia’s largest AI drug licensing deal ($1.3B per asset). She now pioneers collaborative AI innovation across 30+ institutions to transform drug discovery and precision medicine.

秦祯女士是生命科技投资与人工智能交叉领域的战略领袖，拥有逾15年横跨临床医疗、战略咨询、风险投资及AI产业的跨领域经验。现任INTELLIGEN AI首席产业顾问兼首席战略官，主导生物大语言模型生态建设。她拥有西北大学凯洛格商学院MBA及上海交通大学临床医学本硕学位，兼具顶尖医疗专业与商业战略双重背景。曾任阿里健康董事总经理兼创新药投资负责人，主导了超7000万美元的投资，并推动被投企业达成亚洲最大AI药物授权交易（单项目13亿美元）。目前致力于构建30余家机构的AI协同创新网络，加速药物研发与精准医疗突破。